Trial Profile
CD19-specific T Cell Infusion in Patients With B-Lineage Lymphoid Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 Feb 2022
Price :
$35
*
At a glance
- Drugs Anti CD19 chimeric antigen receptor T cell therapy Alaunos Therapeutics (Primary) ; Interleukin-2 (Primary) ; Carmustine; Cytarabine; Etoposide; Melphalan; Rituximab
- Indications Follicular lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- 27 Jun 2020 Status changed from active, no longer recruiting to completed.
- 03 Feb 2020 According to a Precigen media release, Intrexon Corporation has changed its name to Precigen.
- 30 Jan 2020 According to a Ziopharm Oncology media release, data were published online in Clinical Cancer Research.